Medical Condition News

RSS

Healthy lifestyle choices may reduce risk of stroke

Every 40 seconds someone in the United States has a stroke. Stroke is the fourth leading cause of death and the number one cause of adult disability in the country. While stroke often occurs without warning, understanding risk factors and learning to recognize symptoms can potentially save lives and limit damage if a stroke occurs. In recognition of National Stroke Awareness Month, Northwestern Medicine experts encourage consumers learn about their potential risk factors and start making lifestyle decisions that may decrease their likelihood of having a stroke.

16 May 2012

Biomarker test can accurately detect early arthritis symptoms

More than 27 million adults currently suffer from osteoarthritis, which is the most common form of arthritis. In the past, doctors have been unable to diagnose patients with arthritis until they begin to show symptoms, which include joint pain and stiffness. By the time these symptoms are present, it is often too late for preventive and minimally invasive treatment options to be effective. Now, a research team from the University of Missouri's Comparative Orthopaedic Laboratory has found a way to detect and predict arthritis before patients begin suffering from symptoms.

16 May 2012

Avita commences enrollment in ReCell study for hypertrophic dyspigmented scars

Avita Medical Ltd.,the regenerative medicine company, today announced that it has commenced enrolment in the US FDA-approved feasibility study for the use of ReCell Spray-On-Skin in the treatment of hypertrophic dyspigmented scars.

16 May 2012

Palpitations, hypertension strongest risk factors for AF

A large cohort study has found that the strongest risk factors for atrial fibrillation in both men and women were a history of palpitations and hypertension. While hypertension is a well known risk factor for AF, the investigators note that "the impact of self-reported palpitations on later occurrence of AF has not been documented earlier".

16 May 2012

Modest alcohol consumption linked with less evidence of steatohepatitis

NAFLD (non-alcoholic fatty liver disease) is the most common type of liver disease in the developed world, affecting up to one-third of the US population. NAFLD is often associated with obesity and other parameters of the so-called "metabolic syndrome," which is a major risk factor for the development of cardiovascular disease.

16 May 2012

Intriguing links between Snf2l gene and brain developmental disorders

Scientists at the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa) have discovered that mice that lack a gene called Snf2l have brains that are 35 per cent larger than normal.

16 May 2012

EvergreenHealth announces recipients of 2012 Nursing Excellence awards

In celebration of National Nurses Week, EvergreenHealth recently recognized the exceptional care its nursing teams across the organization provide to enrich the health and well-being of each life they touch with the organization's annual Nursing Excellence awards. The organization awarded a group of exemplary caregivers during its nursing awards ceremony on May 8, 2012.

16 May 2012

Partnership for Patients initiative participants launch sprint program to prevent pressure ulcers

Hospitals participating in the Partnership for Patients initiative have launched a program to prevent pressure ulcers.

16 May 2012

Two new mouse models can help treat food allergies

Food allergies pose a serious and growing problem in the West. Many foods can lead to allergic reactions and this situation is further complicated by so-called cross-reactions, whereby an allergy to one particular food can trigger allergic reactions to another food. There are no treatments available for food allergies, but the establishment of two mouse models can be used to develop and test new forms of treatment, for example vaccines.

16 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

First study to compare complication rates after RAPN and LPN

Robot-assisted surgery has replaced another minimally invasive operation as the main procedure to treat kidney cancer while sparing part of the diseased organ, and with comparable results, according to a new research study by Henry Ford Hospital urologists.

16 May 2012

Two specific gene variants speed progression of Parkinson's disease

UCLA researchers may have found a key to determining which Parkinson's disease patients will experience a more rapid decline in motor function, sparking hopes for the development of new therapies and helping identify those who could benefit most from early intervention.

16 May 2012

Positive results from Boston Scientific's Lotus Aortic Valve System trial

Boston Scientific Corporation announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus Aortic Valve System in patients with severe aortic valve disease.

16 May 2012

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.

16 May 2012

Exendin-4 drug effectively suppresses craving for food

A drug made from the saliva of the Gila monster lizard is effective in reducing the craving for food. Researchers at the Sahlgrenska Academy, University of Gothenburg, have tested the drug on rats, who after treatment ceased their cravings for both food and chocolate.

16 May 2012

Link between dietary supplements and increased risk of cancer

Beta-carotene, selenium and folic acid - taken up to three times their recommended daily allowance, these supplements are probably harmless. But taken at much higher levels as some supplement manufacturers suggest, these three supplements have now been proven to increase the risk of developing a host of cancers.

16 May 2012

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.

16 May 2012

BiO2 Medical receives CE Mark approval for Angel Catheter to prevent PE

BiO2 Medical, Inc. a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, announced today that it has received CE Mark approval for the Angel Catheter, a Nitinol Inferior Vena Cava (IVC) filter, permanently attached to a central venous catheter (CVC) for the use of preventing Pulmonary Embolism (PE) in critically ill patients.

16 May 2012

Novelos completes I-131-CLR1404 Phase 1b trial on advanced solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the first cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.

16 May 2012

Svelte completes enrollment in DIRECT drug-eluting stent study

Svelte Medical Systems today announced completion of enrollment in the DIRECT (Direct Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study conducted at four investigational sites in New Zealand.

15 May 2012